Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

295P - Development and validation of M1 substages for previously untreated metastatic nasopharyngeal carcinoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Head and Neck Cancers

Presenters

Sik Kwan Chan

Citation

Annals of Oncology (2019) 30 (suppl_9): ix97-ix106. 10.1093/annonc/mdz428

Authors

S.K. Chan, C.W. Choi, T.C. Chau, S.C. Chau, K.O. Lam, S.Y. Chan, C.C. Tong, W.L. Chan, D.L.W. Kwong, T.W. Leung, M.Y. Luk, A.W.M. Lee, V.H.F. Lee

Author affiliations

  • Department Of Clinical Oncology, LKS Faculty of Medicine, The University of Hong Kong, NA - Pokfulam/HK

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 295P

Background

We aim at subdividing M1 stage to better predict survival of metastatic nasopharyngeal carcinoma (NPC) patients whose outcomes could vary greatly.

Methods

Patients with previously untreated metastatic NPC (training cohort) were recruited prospectively from 2007 to 2018 and were re-staged based on 8th edition of American Joint Committee on Cancer system. All patients had baseline plasma EBV DNA at diagnosis of metastasis. Characteristics of metastases (site, number and size of metastatic lesions) were confirmed by MRI and PET-CT. We used recursive partitioning analysis (RPA) incorporating baseline plasma EBV DNA and/or metastatic characteristics with internal validations to subdivide M1 stage. The two models were externally validated using an independent data set of 67 NPC patients who were non-metastatic at diagnosis but later developed distant metastases after radical treatment (validation cohort). Performance of survival prediction between the two models was compared with paired t-test under 1000 bootstrapping samples.

Results

The training cohort of 69 patients had a median follow-up of 40.8 months and 3-year overall survival (OS) of 36%. Model 1 incorporating pre-treatment plasma EBV DNA subdivided M1 stage into two groups: M1a (EBV DNA ≤2500 copies/ml; OS 74%) and M1b (EBV DNA >2500 copies/ml; OS 17%) (P< .001). Model 2 basing on metastatic site also yielded good subdivision (M1a: no coexisting liver and bone involvement; M1b: coexisting both liver and bone metastases) (P= .023). Multivariable analyses demonstrated only baseline plasma EBV DNA (>2500 copies/ml) (HR 4.7 (95% CI 1.9-11.5); P= .001) and metastatic site (coexisting liver and bone metastasis) (HR 2.2 (1.0-4.7); P= .046) were prognostic of OS. Model 1 demonstrated better model fit in predicting OS (Model 1: mean AIC 246.9 (95% CI 187.8-303.6) vs Model 2: mean AIC 257.7 (200.6-313.2); P< .001). Model 1 also performed better prediction agreement in the validation cohort (Model 1: mean C-index: 0.59 (95% CI 0.53-0.67) vs. Model 2: mean C-index: 0.57 (0.51-0.63); P< .001).

Conclusions

A novel RPA-based M1 stage set incorporating baseline plasma EBV DNA had a significantly better survival prediction, providing important values on prognosis and treatment decision making.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.